newsfilter
← Latest News
GlobeNewswire·

Tvardi Therapeutics to Participate in Upcoming Investor Events

  • Tvardi Therapeutics management will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston on September 9, 2026, featuring 1-on-1 meetings.
  • The company will attend the 2026 Cantor Global Healthcare Conference in New York on September 10, 2026, at 10:55 AM ET, with a fireside chat & 1-on-1 meetings.
  • Tvardi will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 4:30 PM ET, including a company presentation & 1-on-1 meetings.
  • Webcast replays for the corporate presentation & H.C. Wainwright event will be accessible on the Tvardi Investors website for approximately 90 days.
  • Tvardi is developing oral small molecule STAT3 inhibitors to treat inflammatory & proliferative diseases, including ulcerative colitis & hepatocellular carcinoma.
  • TTI-109, an oral prodrug of the first STAT3 inhibitor TTI-101, demonstrated target engagement & immune cell reductions in a Phase 1 healthy volunteer study.
  • The company plans to initiate a clinical trial for TTI-109 in ulcerative colitis pending IND clearance & additional funding availability.
  • Tvardi is currently conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708).